CDKN2A and astrocytoma (excluding glioblastoma): Genomic alterations characterizing astrocytomas include X-linked nuclear protein (ATRX) loss (87%), cyclin-dependent kinase inhibitor 2A/2B (CDKN2A/2B) homozygous deletion (10%), and TP53 mutation (94%).